LTZ Therapeutics

LTZ Therapeutics is a privately held biotechnology company headquartered in Redwood City, California. The company employs 31 people and generates over $10,000 in annual revenue. LTZ Therapeutics specializes in developing innovative immunotherapy treatments for oncology and autoimmune diseases. Their focus is on a novel myeloid engager platform, which utilizes reverse translational science, emerging disease biology, and the potential of myeloid cells, particularly macrophages, to create effective therapies. The company's unique approach leverages the power of myeloid cell subsets, particularly macrophages, to develop groundbreaking treatments for patients with cancer and autoimmune diseases. Their goal is to improve patient lives and ultimately eliminate cancer. For more information about LTZ Therapeutics and their groundbreaking therapies, please visit their website at ltztherapeutics.com.